KathyDMillerMD

Oncology • Indianapolis, IN

Associate Professor of Medicine, Indiana University

Join to view full profile

Dr. Miller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Miller's full profile

Already have an account?

Office
535 Barnhill Dr
# ROUTE473
Indianapolis, IN 46202
Phone+1 317-274-3960

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1994 - 1997
Johns Hopkins UniversityResidency, Internal Medicine, 1991 - 1994
Johns Hopkins University School of MedicineClass of 1991

Certifications & Licensure

IN State Medical License 1994 - 2025
MN State Medical License 1997 - 1999
ND State Medical License 1997 - 1999

Awards, Honors, & Recognition

Indianapolis Monthly Castle Connolly, 2011, 2013

Clinical Trials

Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2002 Jan 29
Completed
Phase 3
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer Start of enrollment: 2005 Sep 01
Terminated
A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment Start of enrollment: 2007 Apr 01
Completed
Phase 1
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer Start of enrollment: 2007 Oct 01
Terminated
Phase 2
Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer Start of enrollment: 2008 Apr 01
Completed
Not Applicable
A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer Start of enrollment: 2008 Jul 01
Completed
Phase 1
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer Start of enrollment: 2008 Nov 01
Completed
Not Applicable
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations Start of enrollment: 2010 Feb 01
Completed
Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2010 Nov 01
Completed
Phase 2
A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer Start of enrollment: 2011 Jan 01
Completed
Phase 1
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC Start of enrollment: 2012 Jul 01
Completed
Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Start of enrollment: 2013 May 31
Completed
Phase 2
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer Start of enrollment: 2013 Mar 01
Completed
Phase 2
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
A Safety Study of SGN-LIV1A in Breast Cancer Patients Start of enrollment: 2013 Oct 22
Completed
Phase 1
A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors Start of enrollment: 2012 Nov 01
Completed
Phase 1
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
Active, not recruiting
Phase 3
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Start of enrollment: 2014 Sep 09
Terminated
Phase 2
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer Start of enrollment: 2020 Apr 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

269 citations
Evaluation of Soy Phytoestrogens for the Treatment of Hot Flashes in Breast Cancer Survivors: A North Central Cancer Treatment Group Trial
Susan K. Quella, Charles L. Loprinzi, Debra L. Barton, James A. Knost, Jeff A. Sloan
Journal of Clinical Oncology. 2000-03-01
108 citations
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Ne...
Noah Kornblum, Fengmin Zhao, Judith Manola, Paula Klein, Bhuvaneswari Ramaswamy
Journal of Clinical Oncology. 2018-04-17
53 citations
[11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers.
Min Wang, Mingzhang Gao, Kathy D. Miller, George W. Sledge, Qi Huang Zheng
Bioorganic & Medicinal Chemistry Letters. 2012-02-15

Journal Articles

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer
Rita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology

Lectures

Using the Neoadjuvant Approach in Developing Novel Therapies in ER+ Breast Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Review and Interpretation of the 2012 San Antonio Breast Cancer Symposium
Indiana University School of Medicine, Indianapolis, Indiana - 1/19/2013
2012 ACCA Northeast Regional Conference
American Academy of Medical Administrators (AAMA), Wynnewood, Pennsylvania - 10/12/2012
2012 Best of ASCO San Diego
American Society of Clinical Oncology(ASCO), San Diego, California - 8/10/2012
2012 Best of ASCO Boston
American Society of Clinical Oncology(ASCO), Boston, Massachusetts - 8/3/2012
Join now to see all

Authored Content

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerJuly 2020

Press Mentions

Impact of Breast Cancer Screening Interval on Stage at Diagnosis and Overall SurvivalSeptember 23rd, 2024
First-Line Ribociclib plus Endocrine Therapy Significantly Improved PFS Among Pre-Menopausal Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Final Analysis Results from the Phase 2 RIGHT Choice TrialJuly 11th, 2024
New Trials in Breast Cancer: Could Your Patient Benefit?May 16th, 2023
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member